Interleukin-2 (IL-2) is a 15-17 KDa glycoprotein that is Interleukin-2 (IL-2) is known to cause xerostomia and produced mainly by activated CD4 cells. It is a novel actiskin manifestations similar to graft-versus-host disease vator of natural killer (NK) cells and T lymphocytes and (GVHD). We therefore evaluated major salivary gland has cytotoxic capacities. (AML). Parotid and submandibular salivary gland IL-2 administration at high doses is associated with sevfunction was assessed before, during and after ILere toxicity including capillary leak syndrome, interstitial 2/IFN-␣ administration by evaluation of the salivary pulmonary congestion, cardiotoxicity, hypotension, general flow rate and the composition of secreted saliva. Sigmalaise, fever, anorexia, myalgia, gastrointestinal disturbnificant reductions in both the resting and stimulated ances and allergic manifestations. [4] [5][6][7][8][9] This toxicity has genparotid and submandibular salivary flow rates were erally been attributed to IL-2-mediated stimulation of effecobserved during IL-2/IFN-␣ immunotherapy compared tor cells of the immune system including T and NK cells, with the pre-and post-therapy values (P Ͻ 0.01), while monocytes and eosinophils as well as secondary cytokine no hyposalivation was observed in the control patients production.
Summary:
Interleukin-2 (IL-2) is a 15-17 KDa glycoprotein that is Interleukin-2 (IL-2) is known to cause xerostomia and produced mainly by activated CD4 cells. It is a novel actiskin manifestations similar to graft-versus-host disease vator of natural killer (NK) cells and T lymphocytes and (GVHD). We therefore evaluated major salivary gland has cytotoxic capacities. [1] [2] [3] IL-2 has been demonstrated to function in patients with hematological malignancies have an anti-tumoral effect in hematological malignancies treated with IL-2 and interferon-␣ (IFN-␣) after including acute and chronic myelogenous leukemia (AML ABSCT. Eleven patients (seven male, four female) of median age 40 (24-47) were evaluated, seven with nonand CML) as well as solid tumors including malignant Hodgkin lymphoma (NHL); one with Hodgkin's disease melanoma, metastatic renal carcinoma and malignant (HD) and three with acute myelogenous leukemia lymphoma. 1, 4 (AML). Parotid and submandibular salivary gland IL-2 administration at high doses is associated with sevfunction was assessed before, during and after ILere toxicity including capillary leak syndrome, interstitial 2/IFN-␣ administration by evaluation of the salivary pulmonary congestion, cardiotoxicity, hypotension, general flow rate and the composition of secreted saliva. Sigmalaise, fever, anorexia, myalgia, gastrointestinal disturbnificant reductions in both the resting and stimulated ances and allergic manifestations. [4] [5] [6] [7] [8] [9] This toxicity has genparotid and submandibular salivary flow rates were erally been attributed to IL-2-mediated stimulation of effecobserved during IL-2/IFN-␣ immunotherapy compared tor cells of the immune system including T and NK cells, with the pre-and post-therapy values (P Ͻ 0.01), while monocytes and eosinophils as well as secondary cytokine no hyposalivation was observed in the control patients production.
2,3,9,10 who underwent ABSCT and did not received IL-2. SialImmunotherapy with high-dose IL-2 in patients with ochemical evaluation revealed a significant increase in metastatic cancer has also resulted in dryness of the mouth, potassium concentration (24.4 ± 0.6 mEq/l to 28.9 ± 1.4 mucositis and reduction in whole saliva output. 11 IL-2 mEq/l) and a significant decrease in sodium concenadministration following autologous as well as allogeneic tration (6.7 ± 2.1 mEq/l to 3.3 ± 1.0 mEq.l) (P Ͻ 0.05) bone marrow transplantation has resulted in the manifesin the stimulated parotid gland saliva secreted during tation of cutaneous and visceral graft-versus-host disease IL-2/IFN-␣ administration. Salivary protein concen-(GVHD) both in animal models and in humans. 11-16 IL-2-trations were not altered by the IL-2/IFN-␣ immunoinduced hyposalivation may thus be due to the GVHD-like therapy. Similar changes were previously observed in effect, since we have recently observed both in a murine mice and humans with chronic GVHD. We conclude model of chronic GVHD and in patients with GVHD a that IL-2 immunotherapy induces major salivary gland major salivary gland dysfunction manifested by hyposalivdysfunction in humans, similar to our previous obseration, reduced salivary flow rates and flattening of the norvations in patients with chronic GVHD, which may indimal salivary flow rate curve. 17, 18 The pathological changes cate similar pathophysiologic mechanisms.
in the oral cavity and salivary glands in chronic GVHD Keywords: interleukin-2; salivary glands; hyposalivresemble the alterations observed in the Sjö gren-like synation; salivary flow rates drome (SS). [19] [20] [21] Furthermore, increased levels of mRNA to IL-2 have recently been detected in the labial salivary glands of patients with SS.
19-21 However, sialometry of the major salivary glands in malignant lymphoma patients receiving relatively low doses of IL-2 (6 × 10 6 IU/m 2 /day) subcutaneously after ABSCT has not yet been studied.
In the present study, we have evaluated the functional after termination of the second course of therapy (Post). and three patients had acute myelogenous leukemia (AML).
The four NHL control patients were evaluated 3.5 Demographic and clinical characteristics, including basic months after ABSCT and the two CML controls were disease, disease status at ABSCT, conditioning regimen and evaluated 2 weeks after initiation of IFN-␣ (3 × 10 6 outcome, are presented in Table 1 . In addition, four age-U/day) therapy. and sex-matched NHL patients who underwent ABSCT but did not receive IL-2/IFN-␣ immunotherapy, and two ageand sex-matched CML patients who underwent ABSCT followed by IFN-␣ therapy, served as controls. Saliometry
Major salivary gland flow rates were determined as pre-IL-2 (interleukin-2) viously described. 18 Specimens were obtained in the mornHuman recombinant IL-2 was kindly provided by Chiron ing. No oral stimulus was permitted for 90 min prior to BV (Amsterdam, The Netherlands). Specific activity was collection. A Carlsdon Crittenden cup was used to obtain approximately 1.5 × 10 7 U/mg protein. IL-2 was supplied parotid saliva. Submandibular (SM) saliva was collected by as a lyophilized powder in 1 mg vials (18 × 10 6 IU) and standardized gentle suction. Unstimulated (resting) saliva reconstituted in sterile water. IU (international units) are was collected on ice. Subsequently, a 2% citric acid solused throughout this report.
ution was applied to the tongue dorsum bilaterally at 30-s intervals. After 2 min the glands were again stimulated while parotid and SM saliva was collected, again on ice
IFN-␣ (Roferon-A)
with continued stimulation. If no flow was observed within Recombinant human IFN-␣ was provided by Hoffman-Lathese 5 min the measure was assumed to be zero. Salivary Roche (Basel, Switzerland). Specific activity was 2 × 10 8 gland flow rates are expressed as volume of saliva secreted U/mg protein. It was supplied as a lyophilized powder and in ml per min. reconstituted in sterile water.
Immunotherapy protocol
Saliochemical analysis Three months after ABSCT, patients were treated with daily subcutaneous injections of IL-2 (3-6 × 10 6 IU), and Saliva samples collected were centrifuged and salivary constituents analyzed. Sodium and potassium were measured IFN-␣ (3 × 10 6 U) for 5 consecutive days each week. Patients received 4 weeks of treatment followed by a 4-by flame photometry (Instrumentation Laboratories) and total protein by spectrophotometic methods (Perkin-Elmer, week rest period and a second 4 week course of treatment.
Major salivary gland evaluation was performed five Norwal, CT, USA) as previously described. a All patients underwent autologous blood stem cell transplantation and received Il-2/IFN-␣ immunotherapy. NHL = non-Hodgkin lymphoma; HD = Hodgkin's disease; AML = acute myelogenous leukemia; CR = complete remission; PR = partial remission; Bu = busulfan; T, Thio = thiotepa; C, Cy = cyclophosphamide; E = etoposide; A = Ara-C; M = melphalan; A&W = alive and well; FAB = FrenchAmerican-British.
Statistical analysis
Statistical significance of the differences in results was evaluated by the Wilcoxon two-sample test.
Results

Subjective evaluation of salivary function
All patients experienced dryness of the mouth during the IL-2/IFN-␣ immunotherapy. They complained about taste aberrations or a burning sensation in the mouth, and felt the necessity to drink or rinse the mouth often. Xerostomia and complaints were similar to those we observed previously in patients with GVHD. 18 No difference in the degree of dryness of mouth was observed between the first and second course of IL-2/IFN-␣ immunotherapy. No complaints of xerostomia were made by the four control patients who underwent ABSCT but did not receive IL-2/IFN-␣ immunotherapy, or by the two CML patients who received IFN-␣ alone.
In most of the patients (9/11) dryness of mouth disappeared spontaneously 10-14 days after cessation of treatment. However, in two patients (Nos 4 and 6, Table 1), xerostomia persisted for more than 6 months.
Oral manifestations
Oral manifestations included mucosal atrophy, mucositis and erosive and ulcerative lesions. In one of the patients (No. 2, Table 2 ) we observed severe swelling of the parotid glands 3 days following IL-2 administration, which necessitated hospitalization and treatment with prednisone (60 mg/day). Cultures were negative. The swelling gradually subsided after 5 days of prednisone therapy.
Parotid salivary flow rates
Significant reductions in both resting and stimulated mean parotid salivary flow rates were observed during the IL-2/IFN-␣ immunotherapy courses compared to pre-and post-treatment values (Figure 1a 
Submandibular salivary flow rates
(resting and stimulated) was observed in the control NHL patients who did not receive IL-2/IFN-␣ immunotherapy The mean submandibular flow rates (both resting and following ABSCT (0.075 ± 0.02 and 0.525 ± 0.065 ml/min, stimulated) were significantly lower during IL-2/IFN-␣ respectively). Similarly, IFN-␣ alone had no effect on the immunotherapy than pre-therapy values ( figure 2a and b) submandibular salivary flow rates (data not shown). Mean (P Ͻ 0.01). In addition, flow rate values were similar dursubmandibular salivary flow rates during IL-2/IFN-␣ thering the second and first course of immunotherapy ( Figure  apy were similar to the values we previously observed 2). The reduction in mean salivary flow rates was reversin patients with chronic GVHD (0.045 ± 0.005 and ible: both resting and stimulated mean submandibular sali-0.21 ± 0.03 ml/min for resting and stimulated flow rates, vary flow rates returned to pre-therapy values 2 weeks folrespectively).
18 lowing termination of Il-2/IFN-␣ immunotherapy ( Figure  2 ). No reduction in mean submandibular salivary flow rates
Sialochemical analysis
Sialochemical analysis showed a significant increase in potassium (24.4 ± 0.6 to 28.9 ± 1.4 mEq/l) and a significant decrease in sodium (6.7 ± 2.1 to 3.3 ± 1.0 mEq/l) (P Ͻ 0.05) in parotid saliva stimulated during IL-2/IFN-␣ therapy compared to the pre-therapy values ( Table 2) . No differences were observed in total protein content following IL-2/IFN-␣ administration (Table 2) . These results are similar to our previous findings in a murine model of chronic GVHD. 17 No changes were observed in the potassium, sodium or total protein content of simulated parotid saliva from the control patients who did not receive cytokine immunotherapy or were trated with IFN-␣ alone (data not shown).
Discussion
In the present study, we observed major salivary gland dysfunction in patients who received relatively low doses of IL-2/IFN-␣ immunotherapy following ABSCT. The function of both parotid and submandibular glands decreased significantly. The resting parotid and submandibular flow rates dropped by 83-95% and 73-83%, respectively compared to pre-therapy values, while the stimulated flow rate dropped by 48-65% and 52-56%, respectively. In the control patients who received no immunotherapy or who were treated with IFN-␣ alone we observed no hyposalivation, which highlights IL-2 as the cytokine responsible for this phenomenon. Mucositis and diminution of whole saliva output was previously reported in a small group of disseminated melanoma patients who received continuous i.v. infusion of high dose IL-2 (18 × 10 6 IU/m 2 ) for 5 days.
11
However, functional resting and stimulated sialometry studies of the major salivary glands were not performed. The IL-2-induced reduction in major salivary gland flow rates may be mediated via activation of cytotoxic cells, induction of cytokines like TNF␣ and IL-6, or the release of free radicals. [22] [23] [24] [25] [26] [27] We have previously demonstrated increased lymphoid infiltration of both the parotid and the submandibular glands which correlated with salivary gland hypofunction in mice receiving IL-2. 22 The marked swelling of the parotid glands in one of our patients following IL-2 administration is in accordance with this finding. IL-2 may alone has been shown to cause marked inhibition of human reported with regard to salivary hypofunction. 32 The IL-2- with our previous publications. 
